

Neuland Laboratories Limited
Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034.
Telangana, India.

Tel: 040 3021 1600 / 23551081
Fax: 040 3021 1602
Email: neuland@neulandlabs.com
www.neulandlabs.com

March 1, 2017

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB
Series: EQ

Dear Sir(s),

Sub: Clarification / Information on the published news

Ref: News Item which appeared on ET NOW dated March 1, 2017 captioned "US FDA Grant Priority Review for SD-809"

We refer to your letter dated March 1, 2017 regarding clarification on the above referred news item which appeared on 'ET Now'.

In this regard, we would like to confirm that the Company has been disclosing all relevant information to the Stock Exchanges under Regulation 30 and there is no information as such that has not been announced to the Stock Exchanges under Regulation 30.

Further, we would like to state that our relationships with our customers both under the Custom Manufacturing Solutions (CMS) and the Generic Active Pharmaceutical Ingredients (API) manufacturing are bound by confidentiality clauses. All our communications to the exchanges and the investors in the past have been bound by these agreements with our customers.

Please further note that the approval for the aforesaid product, is not received by Neuland Laboratories Limited and therefore the Company cannot give any comments on the development.

This is for your information and records.

Thanking you,

Yours faithfully,
For Neuland Laboratories Limited


Sarada Bhamidipati
Company Secretary

